A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

NCT ID: NCT04998786

Last Updated: 2025-04-06

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 75 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-14
• Study Completion Date: 2030-01-01

Brief Summary

This is a phase II, multicenter, open-label study to evaluate the rate of patients achieving very good partial response (VGPR) or better to the oral combination Iberdomide Ixazomib Dexamethasone in elderly patients with multiple myeloma at first relapse .

The patient population will consist of adult men and women more than 70 years, who meet eligibility criteria.

Following the screening period, patients will be enrolled and treated then, they will receive therapy with Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and Ixazomib until progression.

Conditions

Multiple Myeloma at First Relapse

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

assessment of treatment Ixazomib, dexamethasone, iberdomide

Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and Ixazomib until progression

Group Type: EXPERIMENTAL

Ixazomib

Intervention Type: DRUG

Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress

Iberdomide

Intervention Type: DRUG

Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress

Dexamethasone Oral

Intervention Type: DRUG

Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22

Interventions

Ixazomib

Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress

Intervention Type: DRUG

Iberdomide

Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress

Intervention Type: DRUG

Dexamethasone Oral

Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age > 70 years

2. Eastern Collaborative Oncology Group (ECOG) performance score of ≤2

3. Life expectancy > 6 months

4. Voluntary written informed consent must be given before performance of any study-related procedure not part of normal medical care, with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.

5. Symptomatic multiple myeloma (MM) at first relapse, as defined below:

• Symptomatic multiple myeloma according to international criteria.(Rajkumar et al, 2014)
• Relapsed MM is defined as previously treated MM that progresses and requires initiation of salvage therapy.

6. Subject must have received one prior line of therapy for at least 3 cycles.

7. Subject has measurable disease at Screening, defined at least one of the following:

• Serum M-protein ≥ 0.5 gram (g)/deciliter (dL), OR
• Urine M-protein ≥ 200 mg in 24 hours, OR
• Serum immunoglobulin free light chain (FLC) ≥ 10 mg/dL provided serum FLC ratio is abnormal.

8. Subjects must meet the following laboratory parameters, per laboratory reference range (performed at most 15 days before cycle 1 day 1):

• Absolute neutrophil count (ANC) ≥ 1000/microliter (μL). Subjects may use growth factor support to achieve ANC eligibility criteria.
• Platelet count ≥ 75,000 /mm3 for subjects in whom < 50% of bone marrow nucleated cells are plasma cells; or a platelet count ≥ 50,000/mm3 for subjects in whom > 50% of bone marrow nucleated cells are plasma cells. It is not permissible to transfuse subjects to achieve minimum platelet counts within 3 days before study.

--AST and ALT ≤ 3 × upper limit of normal (ULN).

• Total bilirubin ≤ 1.5 × ULN. Subjects with documented Gilbert's syndrome may have bilirubin > 1.5 × ULN with the approval of the Primary Therapeutic Area Medical Director
• Creatinine clearance (CrCl) ≥ 30 milliliter (mL)/minute (min) (using Cockroft and Gault Formula)

9. Patient should comply with Celgene's pregnancy prevention plan for Iberdomide (please see appendix 8 Iberdomide Pregnancy Prevention Plan for subjects in clinical trials)

10. Female patients who:

• are postmenopausal for at least 24 months before the screnning visit, OR
• are surgically sterile (have undergone a hysterectomy or bilateral oophorectomy)

11. Men even if surgically sterilized must agree to not father a child and agree to practice complete abstinence or to use a condom during therapy and dose interruptions and for 90 days after the last dose of study drug, even if they have had a successful vasectomy, if their partner is of childbearing potential or pregnant.

1. Subject is refractory to bortezomib, defined as progression on or within 60 days of the last dose of bortezomib.

2. Subject has had prior treatment with ixazomib, carfilzomib, pomalidomide or iberdomide

3. Subject has any of the following conditions:

• Non-secretory or oligo-secretory MM
• Light chain Amyloidosis (AL Amyloidosis)
• POEMS syndrome Waldenström macroglobulinemia

4. Known Human Immunodeficiency Viral (HIV) infection

5. Active hepatitis B or C infection based on blood screen tests

6. Significant cardiovascular or pericardial disease, including uncontrolled angina, hypertension, arrhythmia, recent myocardial infarction within 6 months, congestive, heart failure New York Heart Association (NYHA) Class ≥ 3

7. Major surgery within 4 weeks prior screening

8. Acute infections requiring parenteral therapy (antibiotic, antifungal or antiviral) within 14 days

9. ≥ Grade 3 Peripheral neuropathy or grade 2 with pain

10. Uncontrolled diabetes or uncontrolled hypertension within 14 days

11. Any other medical condition that, in the opinion of the Investigator, would adversely affect the subject's participation in the study

12. Subject has a history of other active malignancies, including myelodysplastic syndrome (MDS), within the past 3 years prior to study entry, with the following exceptions:

• Adequately treated in situ carcinoma of the cervix uteri or the breast,
• Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin,
• Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen (PSA) levels off treatment,
• Previous malignancy with no evidence of disease confined and surgically resected (or treated with other modalities) with curative intent and unlikely to impact survival during the duration of the study.

13. Known intolerance to steroid therapy

14. Serious medical or psychiatric illness likely to interfere with participation in study

15. Incidence of gastrointestinal disease that may significantly alter the absorption of oral drugs

16. Subjects unable or unwilling to undergo antithrombotic prophylactic treatment

17. Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision

• Minimum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nantes University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Cyrille Touzeau

Role: PRINCIPAL_INVESTIGATOR

Nantes University Hospital

Locations

CHR

Annecy, , France

CH de la cote basque

Bayonne, , France

CHRU Hopital Haut Lévêque

Bordeaux, , France

CHU

Caen, , France

CHU

Clermont-Ferrand, , France

CHRU

Dijon, , France

CHD les Oudairies

La Roche-sur-Yon, , France

CHRU Lille

Lille, , France

CHU

Limoges, , France

CH Lyon Sud

Lyon, , France

CHRU

Nancy, , France

CHU

Nantes, , France

Hopital de l'archet

Nice, , France

CHU Henri Mondor

Paris, , France

Hopital St Antoine

Paris, , France

Hôpital Cochin

Paris, , France

University Hospital

Poitiers, , France

CHRU

Rennes, , France

ICANS

Strasbourg, , France

CHU

Toulouse, , France

CHRU Bretonneau

Tours, , France

Countries

France

Other Identifiers

2021-001587-13

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

RC21_0169

Identifier Type: -

Identifier Source: org_study_id